This week, the 21st Century Cures Act sailed through the House and is headed to the Senate next week. The legislation will invest more than $6 billion in public health and medical research over the next decade.
The pain around reimbursement delays have been reported on for years in independent pharmacy circles and is a common theme whenever two or more pharmacists are gathered at an event. Now, the message is getting out to a broader audience, with this recent story on NPR’s .
The theme? A familiar one. Generics are getting more expensive. PBMs are often three months behind costs when it comes to reimbursements. And one PBM rep, unsurprisingly, blames the independents for “charging as much as they want” and positioning themselves as the white knights who are ensuring greater access to affordable medications. Shades of David and Goliath.